Martin S Maron MD

Adult Congenital Heart Disease

Assistant Professor of Medicine

Summary

Martin Maron, MD, serves as the Director of the Hypertrophic Cardiomyopathy Center and the Co-Director of the Cardiac CT and MRI program at Tufts Medical Center and Associate Professor at Tufts University School of Medicine. His specialties include cardiac imagining, hypertrophic cardiomyopathy, and cardiac magnetic resonance imaging. He was the Hypertrophic Cardiomyopathy Association’s 2011 Clinician of the Year, and currently serves on the association’s Board of Directors. He is board certified in Cardiovascular Disease and Internal Medicine.

Tufts Medical CenterFellowship, Cardiovascular Disease, 2002 - 2005
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2001
Tulane University School of MedicineClass of 1999

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Fellow (FACC) American College of Cardiology

PubMed

Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy.
Ayman R Fath, Amro Aglan, Martin S Maron, Jason S Phillips, Barry J Maron
International Journal of Cardiology. 2025-05-01
Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID-19 Pandemic.
Ahmed Sayed, Barry J Maron, Ethan J Rowin, Martin S Maron
Journal of the American Heart Association. 2025-04-01
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.
Bryton J Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen
Journal of the American Heart Association. 2025-03-18

Journal Articles

Mini-Focus Issue: Hypertrophic Cardiomyopathy State-of-the-Art Review Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy
Martin S Maron, Barry J Maron, James E Udelson, Ethan J Rowin, ScienceDirect

Lectures

HCM and its Many Variations: When to Suspect and How to Diagnose?
2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019

Other

Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy
Maron MS, Elliott PM
http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-evaluation-of-hypertrophic-ca
UpToDate, Wolters Kluwer Health - 2012-12-13
Overview of hypertrophic cardiomyopathy management including treatment of special problems
Maron MS
http://www.uptodate.com/contents/overview-of-hypertrophic-cardiomyopathy-management-including-treatm
UpToDate, Wolters Kluwer Health - 2012-12-06

Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic CardiomyopathyOctober 28th, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCMOctober 28th, 2024
‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCMOctober 2nd, 2024
Join now to see all

Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMRBETH ISRAEL DEACONESS MEDICAL CENTER2025–2030
Cardiac MR-Based Risk Stratification for Heart Failure and Atrial Fibrillation in HCMBETH ISRAEL DEACONESS MEDICAL CENTER2021–2025
Clinical And Therapeutic Implications Of Fibrosis In Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2007–2011